EPO Patent Publication EP4147696A1 - Chimeric Protein

The European Patent Office published patent application EP4147696A1 on March 11, 2026, concerning chimeric proteins. The application lists Autolus Limited as the applicant and details inventors and IPC classifications related to protein and gene technology.

Prostate Cancer Treatment: Virus, PD-1 Inhibitor, Immune Activator Combination

The European Patent Office has published patent application EP4358984A1 detailing a combination therapy for prostate cancer. This treatment involves an oncolytic virus, a PD-1 inhibitor, and an activator of the innate immune system. The patent was published on March 11, 2026.

Bacteriocin Application EP4346870A1 Published

The European Patent Office published application EP4346870A1 concerning a bacteriocin for new applications on March 11, 2026. The application was filed by Syngulon S.A. and lists Philippe Gabant and Felix Jaumaux as inventors. This publication pertains to intellectual property and potential therapeutic applications.

EPO Patent Publication: Opioid Agonist Peptides

The European Patent Office published patent application EP4092038A1 on March 11, 2026, related to opioid agonist peptides and their uses. The application lists Protagonist Therapeutics, Inc. as the applicant.

EPO Patent: Periostin Antibody for Treating Inflammation, Fibrosis, Lung Diseases

The European Patent Office has published patent application EP4301776A1 concerning the use of a periostin antibody for treating inflammation, fibrosis, and lung diseases. The patent was published on March 11, 2026, and lists the Centre National de la Recherche Scientifique (CNRS) and Université d'Orléans as applicants.

EPO Patent Application for Antimicrobial Peptoid Copolymers

The European Patent Office (EPO) has published a patent application (EP4294821A1) for antimicrobial cationic peptoid and N-substituted peptidic copolymers, their preparation, and uses. The application was filed on March 11, 2026, by UNIVERSITE DE BORDEAUX and other research institutions.

Patent EP4397684A1: Anti-Human TSLP Monoclonal Antibody

The European Patent Office has published patent application EP4397684A1 concerning an anti-human TSLP monoclonal antibody and its use. The application was filed by Qyuns Therapeutics Co., Ltd. and lists multiple inventors.

EPO Patent EP4397683A1: Anti-Human Interleukin-33 Monoclonal Antibody

The European Patent Office has published patent application EP4397683A1 for an anti-human Interleukin-33 monoclonal antibody and its use. The patent application was filed by Qyuns Therapeutics Co., Ltd. and lists multiple inventors.

EPO Patent Application: Mesothelin Binding Molecule

The European Patent Office has published patent application EP4269442A1 concerning a mesothelin binding molecule and its application. The application was filed by Zhejiang Nanomab Technology Center Co. Ltd. and lists multiple inventors. The publication date is March 11, 2026.

Patent EP4247855A1: Anti-CD73 Antibody, Drug Conjugate, and Use

The European Patent Office has published patent application EP4247855A1 concerning an anti-CD73 antibody, antibody-drug conjugate, and its therapeutic use. The patent was applied for by Bliss Biopharmaceutical (Hangzhou) Co., Ltd. and published on March 11, 2026.